ABBVIE ANNOUNCES PLANS TO PROCEED TO PHASE 3 EVALUATION OF ELAGOLIX IN PATIENTS WITH UTERINE FIBROIDS
AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the completion of a Phase 2b clinical trial evaluating the safety...
Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015
Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem/Cilastatin for Treatment of Serious Bacterial Infections known as MSD outside the United...
Vyome Biosciences Presents Research Data on Development of Novel Antibiotics and Antifungal Agents to American Society of Microbiology
Vyome Biosciences, a dermatology based innovative bio-pharmaceutical company, which is pioneering the development of next generation antibiotics and antifungal agents that target antimicrobial resistance...
Long-Term, 7-Year Study of Nulojix® Regimen Demonstrates Statistically Significant Relative Risk Reduction of Death or Graft Loss over Cyclosporine Regimen in Kidney Transplant
Bristol-Myers Squibb Company announced results from a 7-year, long-term follow-up from a prospective, randomized Phase III trial (BENEFIT) in kidney transplant patients, which demonstrated...
Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference
The Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015, in Las Vegas. Doug Manion, head, Specialty Development, will...
ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients...
Today announced that primary endpoints were successfully met in ALLY-1, a Phase III clinical trial evaluating a 12-week regimen of daclatasvir and sofosbuvir once-daily...
Combination Drug Development and Five Year New Chemical Entity (NCE) Exclusivity
The US Food and Drug Administration (FDA) recently announced that fixed-combination drugs (FCD) comprised of at least one NCE will be eligible for five...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...